Purpose: We aimed to evaluate the best‑corrected visual acuity (BCVA) and assess improvement of central macular thickness (CMT) in
patients with diffuse diabetic macular edema (DDME) after an intravitreal injection of bevacizumab (Avastin®) alone, or followed by modified
grid macular laser photocoagulation. Subjects and Methods: This was a randomized prospective interventional study that included 78
eyes of 40 patients with DDME, divided into two groups of interventions: Group A received bevacizumab (Avastin®) injections monthly for
3 months then pro re nata, and Group B received bevacizumab as Group A but followed by grid macular laser photocoagulation 2 weeks after
the first injection. Patients were observed monthly for a 12‑month period and their BCVA, intraocular pressure, and CMT were recorded.
Results: Compared with the baseline, there was a significant decrease of CMT in both groups of patients (−138.3 ± 40.15 vs. −156.5 ± 33.47,
respectively). The improvement in ME was more in the combined group than the Avastin® group (P < 0.0001). After 12‑month follow‑up, the mean
average change in visual acuity letter score was significantly improved in both groups (P < 0.018 and < 0.002, respectively). Conclusion: Combined
Avastin® and modified grid macular photocoagulation led to more stable improvement in the treatment of eyes with DDME. |
